Product image of Levosimendan Fresenius Kabi (Levosimendan) supplied by GNH India

Levosimendan Fresenius Kabi

Active Ingredient:
Levosimendan
Origin:
EU

Levosimendan Fresenius Kabi (Levosimendan)

Levosimendan, the active ingredient in Levosimendan Fresenius Kabi, is a calcium sensitizer and potassium channel opener presented as an intravenous formulation for hospital use. It increases cardiac contractility and induces vasodilation in patients with acute decompensated heart failure.

GNH India supplies Levosimendan Fresenius Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and cardiac care units worldwide, with the product sourced from the European Union market. All shipments adhere to stringent quality standards and regulatory requirements.

Manufacturer / TM Owner

Fresenius Kabi Ab

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Levosimendan is used as an inotropic agent for the management of acute decompensated heart failure.
  • Acute decompensated heart failure: improves cardiac output and relieves symptoms of congestion.
  • Severe chronic heart failure with low output: provides short‑term hemodynamic support when conventional therapy is insufficient.
  • Cardiogenic shock (adjunct): may be added to stabilize blood pressure and cardiac performance in critical care settings.

How It Works

  • Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby enhancing contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation and reducing cardiac afterload, which together improve overall cardiac performance.

Side Effects

Levosimendan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Hypotension: transient drop in blood pressure.
  • Nausea or vomiting: gastrointestinal discomfort.
  • Tachycardia: increased heart rate.
  • Dizziness: related to blood pressure changes.
  • Flushing: warm sensation on skin.

Serious or Rare Side Effects

  • Ventricular arrhythmias: potentially life‑threatening rhythm disturbances.
  • Myocardial ischemia: reduced blood flow to heart muscle.
  • Severe hypotension: marked blood pressure fall requiring intervention.
  • Pulmonary edema: fluid accumulation in lungs.
  • Sudden cardiac death: rare but fatal outcome.
  • Anaphylactic reaction: severe allergic response.

Precautions & Warnings

  • Levosimendan requires careful monitoring and specific safety measures before and during therapy.
  • Monitor blood pressure: watch for hypotension and adjust infusion rate.
  • Observe cardiac rhythm: detect arrhythmias promptly.
  • Assess renal function: dose may need adjustment in severe impairment.
  • Avoid concurrent strong vasodilators: risk of additive hypotensive effect.
  • Use cautiously after recent myocardial infarction: potential for ischemia.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other cardiovascular agents, necessitating vigilance.

Major Interactions (Avoid)

  • Sodium nitroprusside: additive hypotensive effect.
  • Other inotropes (e.g., dobutamine): increased risk of arrhythmias.
  • Potassium channel blockers (e.g., nicorandil): excessive vasodilation.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt inotropic response.
  • ACE inhibitors or ARBs: potential for enhanced blood pressure reduction.
  • Diuretics: electrolyte shifts may affect cardiac stability.

Frequently Asked Questions

Levosimendan Fresenius Kabi is an intravenous inotropic medication indicated for the short‑term treatment of acute decompensated heart failure. It helps improve cardiac contractility and reduces vascular resistance, supporting patients who have severe symptoms despite standard therapy.

Levosimendan increases the sensitivity of cardiac troponin C to calcium, which enhances the strength of heart muscle contraction without raising intracellular calcium. At the same time, it opens ATP‑sensitive potassium channels in blood vessels, causing vasodilation and lowering the workload on the heart.

The dosing regimen for levosimendan is determined by the prescribing physician based on the patient’s clinical condition, weight, and response. The medication is administered intravenously under continuous monitoring in a hospital setting.

The safety of levosimendan in pregnancy and lactation has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Unlike traditional catecholamine inotropes, levosimendan enhances contractility without increasing intracellular calcium, which may reduce the risk of calcium‑mediated toxicity. Its combined vasodilatory effect also lowers afterload, offering a distinct hemodynamic profile compared with agents such as dobutamine or milrinone.

Levosimendan Fresenius Kabi must be stored at 2‑8 °C. Keep the vials refrigerated, protect them from light, and avoid freezing or shaking the solution. Follow the packaging label for any additional handling instructions.

Levosimendan is given as an intravenous infusion, usually started with a loading dose followed by a continuous maintenance infusion. Administration is performed in a monitored clinical environment, and infusion rates are adjusted according to blood pressure, heart rate and therapeutic response.

The most serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia and, in rare cases, sudden cardiac death. Continuous cardiac and hemodynamic monitoring is essential to detect and manage these events promptly.

Levosimendan is contraindicated in patients with known hypersensitivity to the drug, severe hypotension unresponsive to treatment, and those with significant obstructive arterial disease where vasodilation could worsen perfusion. Clinicians must evaluate each patient’s medical history before initiating therapy.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Levosimendan

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT